ARNA Arena Pharmaceuticals Inc.

+2.84  (+5%)
Previous Close 52.88
Open 53.24
Price To Book 2.31
Market Cap 2,776,258,027
Shares 49,825,162
Volume 541,421
Short Ratio
Av. Daily Volume 531,468

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 27, 2012.
Phase 2/3 trial to be initiated 2019.
Olorinab (APD371)
Pain associated with Crohn's disease
Phase 3 commencement of dosing announced June 17, 2019.
Etrasimod - ELEVATE UC 52
Ulcerative colitis
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Pulmonary Arterial Hypertension
Phase 2 trial to be initiated 2019.
Atopic dermatitis (AD)

Latest News

  1. 25 Biggest Marijuana Companies in the World
  2. Edited Transcript of ARNA earnings conference call or presentation 7-Aug-19 8:30pm GMT
  3. This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged
  4. Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet
  5. Arena Pharmaceuticals Inc (ARNA) Q2 2019 Earnings Call Transcript
  6. Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials
  7. Is Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) A High Quality Stock To Own?
  8. United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y
  9. Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7
  10. Top Marijuana Stocks on the NASDAQ
  11. Analysts Estimate Arena Pharmaceuticals (ARNA) to Report a Decline in Earnings: What to Look Out for
  12. Arena Pharmaceuticals (ARNA) Upgraded to Buy: Here's Why
  13. Arena Pharmaceuticals Announces First Subject Dosed in CAPTIVATE Phase 2 Trial Evaluating Olorinab in Abdominal Pain Associated with Irritable Bowel Syndrome
  14. Should Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Be Your Next Stock Pick?
  15. A Company's First Profit Can Mean Big Profits for Investors
  16. Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
  17. Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
  18. Did Hedge Funds Drop The Ball On Arena Pharmaceuticals, Inc. (ARNA)
  19. Edited Transcript of ARNA earnings conference call or presentation 8-May-19 8:30pm GMT
  20. Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19